Korenstein, Deborah http://orcid.org/0000-0003-1859-0574
Harris, Russell
Elshaug, Adam G
Ross, Joseph S
Morgan, Daniel J
Cooper, Richelle J
Cho, Hyung J
Segal, Jodi B
Funding for this research was provided by:
National Cancer Institute (P30 CA008748-50)
National Institute on Aging (K24 AG049036-01A1)
Article History
Received: 7 September 2020
Accepted: 1 January 2021
First Online: 21 January 2021
Compliance with Ethical Standards
:
: DK reports that her spouse serves on the Scientific Advisory Boards of Vedanta Biosciences and Opentrons and does consulting work for Takeda. AGE holds the HCF Research Foundation Professorial Fellowship and has received direct income from providing low-value care-related data analytics and advice to the following: Australian state government health departments—Victoria, Queensland; Australian Dept of Veterans Affairs; Medibank Ltd.; Private Healthcare Australia (PHA); Australian Defence Force Joint Health Command. AGE receives direct income as a Ministerial appointee to the Australian Government Department of Health’s Medicare Benefits Schedule (MBS) Review Taskforce, as a Board Member of the New South Wales Bureau of Health Information, and as advisor to Cancer Australia. He is a member of the Expert Advisory Committee for Evidence-based Interventions (NICE, NHSCC, NHS Improvement and Academy of Medical Royal Colleges). In the past 36 months, JSR received research support through Yale University from Medtronic, Inc. and the Food and Drug Administration (FDA) to develop methods for postmarket surveillance of medical devices (U01FD004585), from the Centers of Medicare and Medicaid Services (CMS) to develop and maintain performance measures that are used for public reporting (HHSM-500-2013-13018I), and from the Blue Cross Blue Shield Association to better understand medical technology evaluation; Dr. Ross currently receives research support through Yale University from Johnson and Johnson to develop methods of clinical trial data sharing, from the Food and Drug Administration to establish Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938), from the Medical Device Innovation Consortium as part of the National Evaluation System for Health Technology (NEST), from the Agency for Healthcare Research and Quality (R01HS022882), from the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) (R01HS025164, R01HL144644), and from the Laura and John Arnold Foundation to establish the Good Pharma Scorecard at Bioethics International and to establish the Collaboration for Research Integrity and Transparency (CRIT) at Yale. DJM reports funding from the National Institutes of Health, the Centers for Disease Control and Prevention, the Agency for Healthcare Research and Quality (AHRQ) and US Department of Veterans’ affairs (VA). RJC receives grant support from PCORI and from the American College of Emergency Physicians. Other authors report no potential conflicts of interest.
Free to read: This content has been made available to all.